A trans -translation inhibitor that targets ribosomal protein bL12 kills Mycobacterium tuberculosis
Journal of Bacteriology · 2025
DOI: 10.1128/jb.00236-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Bacteriology, 2025. Verfasst von Akanksha Varshney und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biosciences, The University of Texas at Austin, Austin, Texas, USA. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Ribosomal Proteins, Bacterial Proteins, Antitubercular Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIGMS NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
New antibiotics with novel mechanisms of action are needed to treat infections by multidrug-resistant strains of Mycobacterium tuberculosis . Here, we show that KKL-1005, an anti-tubercular triazole-based molecule, binds to ribosomal protein bL12 and specifically inhibits the trans -translation ribosome rescue pathway, a process essential for the survival of M. tuberculosis . Our data demonstrate that KKL-1005 binds to the N-terminal domain of bL12, both in vitro and in bacterial cells, and specifically inhibits trans -translation and not normal translation. These results suggest that tmRNA-SmpB interacts with bL12 differently from tRNA and raise the possibility of developing antibiotics targeting bL12. IMPORTANCE Tuberculosis continues to be a leading cause of death worldwide, and antibiotics that target new pathways are urgently needed. trans -Translation is a ribosome rescue pathway required for the survival of Mycobacterium tuberculosis . We identified a small molecule, KKL-1005, that specifically inhibits trans -translation without affecting translation from a library of compounds that prevent the growth of M. tuberculosis . KKL-1005 targets bacterial ribosomal protein bL12, which is essential for the recruitment and activation of GTPase translation factors. The specificity of KKL-1005 for trans -translation indicates that bL12 interacts differently with the translation machinery during trans -translation than during canonical translation. KKL-1005 is bactericidal against M. tuberculosis , suggesting that inhibiting trans -translation by targeting bL12 is a new strategy for developing antibiotics against drug-resistant infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biosciences, The University of Texas at Austin, Austin, Texas, USA.
- Department of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, Pennsylvania, USA.
ORCID-Profile: Akanksha Varshney, Kenneth C Keiler
Förderung
- NIAID NIH HHS
- NIGMS NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Institute of General Medical Sciences
Zitieren
APA
Varshney, A., Alumasa, J. N., Miller, A., & Keiler, K. C. (2025). A trans -translation inhibitor that targets ribosomal protein bL12 kills Mycobacterium tuberculosis. Journal of Bacteriology. https://doi.org/10.1128/jb.00236-25
Vancouver
Varshney A, Alumasa JN, Miller A, Keiler KC. A trans -translation inhibitor that targets ribosomal protein bL12 kills Mycobacterium tuberculosis. Journal of Bacteriology. 2025. doi:10.1128/jb.00236-25
BibTeX
@article{Varshney2025,
author = {Varshney, Akanksha and Alumasa, John N and Miller, Amber and Keiler, Kenneth C},
title = {A trans -translation inhibitor that targets ribosomal protein bL12 kills Mycobacterium tuberculosis},
journal = {Journal of Bacteriology},
year = {2025},
doi = {10.1128/jb.00236-25}
}
EUVIMED